Sigilon Therapeutics, Inc.
SGTX · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $12,944 | $9,599 | $13,374 | $14,155 |
| % Growth | 34.8% | -28.2% | -5.5% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $12,944 | $9,599 | $13,374 | $14,155 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $37,631 | $65,069 | $53,488 | $48,108 |
| G&A Expenses | $18,979 | $20,166 | $12,528 | $10,170 |
| SG&A Expenses | $18,979 | $20,166 | $12,528 | $10,170 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $55 | -$89 | -$6 |
| Operating Expenses | $56,610 | $85,235 | $66,016 | $58,278 |
| Operating Income | -$43,666 | -$75,636 | -$52,642 | -$44,123 |
| % Margin | -337.3% | -788% | -393.6% | -311.7% |
| Other Income/Exp. Net | $105 | -$1,675 | -$1,966 | $198 |
| Pre-Tax Income | -$43,561 | -$77,311 | -$54,608 | -$43,925 |
| Tax Expense | -$105 | $925 | $259 | $644 |
| Net Income | -$43,456 | -$78,236 | -$54,867 | -$44,569 |
| % Margin | -335.7% | -815% | -410.3% | -314.9% |
| EPS | -1.34 | -31.92 | -22.67 | -27.53 |
| % Growth | 95.8% | -40.8% | 17.7% | – |
| EPS Diluted | -1.34 | -31.92 | -22.67 | -27.53 |
| Weighted Avg Shares Out | 32,406 | 2,451 | 2,420 | 1,619 |
| Weighted Avg Shares Out Dil | 32,406 | 2,451 | 2,420 | 1,619 |
| Supplemental Information | – | – | – | – |
| Interest Income | $946 | $258 | $312 | $1,058 |
| Interest Expense | $2,290 | $1,988 | $1,202 | $650 |
| Depreciation & Amortization | $2,395 | $313 | $223 | $1,727 |
| EBITDA | -$38,876 | -$75,010 | -$53,183 | -$42,396 |
| % Margin | -300.3% | -781.4% | -397.7% | -299.5% |